Short-Acting B2 Agonists Market Report 2026

The short-acting b2 agonists market size has grown steadily in recent years. It will grow from $4.4 billion in 2025 to $4.58 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to high asthma prevalence, emergency respiratory care needs, fast-acting bronchodilator demand, hospital-based treatment protocols, generic drug availability.

The short-acting b2 agonists market size is expected to see steady growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to air pollution increase, urban respiratory disease burden, growth in home inhaler use, pediatric asthma cases, outpatient respiratory care expansion. Major trends in the forecast period include continued use as first-line rescue medication, rising asthma and copd prevalence, preference for inhalation-based delivery, growth of homecare respiratory treatment, expansion of generic saba products.

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to drive the growth of the short-acting β2-agonists (SABA) market in the coming years. COPD is a long-term lung condition that causes breathing difficulties and reduced airflow, primarily due to prolonged exposure to harmful gases or cigarette smoke. Its increasing prevalence is largely linked to rising exposure to air pollution, as long-term inhalation of particulate matter and toxic gases can damage lung tissue and accelerate disease progression. Short-acting β2-agonists are used in COPD to provide rapid relief from symptoms such as shortness of breath by relaxing airway muscles. They act as rescue medications during flare-ups but are not intended for long-term control. For example, in December 2023, a study published in JAMA Network Open, a medical journal by the American Medical Association, projected that global COPD cases could reach nearly 600 million by 2050, representing a 23% increase in prevalence. Therefore, the growing prevalence of COPD is boosting the short-acting β2-agonists market.

Major companies in the short-acting β2-agonists market are focusing on developing advanced products, such as pressurized metered-dose inhalers (pMDIs), to manage acute symptoms effectively. Pressurized metered-dose inhalers are handheld devices that deliver a precise dose of medication to the lungs in aerosol form using a propellant-driven spray, commonly used to treat respiratory conditions like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced US FDA approval for Airsupra (albuterol/budesonide). Airsupra is a first-in-class pMDI that combines two active ingredients in a fixed-dose formulation: albuterol, a short-acting β2-agonist, for rapid bronchodilation, and budesonide, an inhaled corticosteroid, to reduce inflammation. This combination is approved in the US for as-needed treatment and prevention of bronchoconstriction in adults with asthma and helps reduce the risk of exacerbations, providing a comprehensive approach to asthma management.

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based manufacturer of short-acting β2-agonists, partnered with Launch Therapeutics Inc. to accelerate Teva’s ICS clinical research program-SABA (TEV-248). Through this collaboration, Teva aims to fast-track the development and commercialization of its dual-action asthma rescue inhaler, offering a more effective treatment for both adult and pediatric asthma patients. Launch Therapeutics Inc. is a US-based clinical development company.

Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the short-acting b2 agonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the short acting b2 agonists market by increasing the cost of imported APIs and inhaler components used in respiratory drug manufacturing. These impacts are most pronounced in Asia Pacific and Europe, where generic producers rely heavily on cross border sourcing. Rising tariff related expenses have increased pricing pressure and margin constraints for generic manufacturers. This has influenced procurement planning and competitive positioning across respiratory care markets. However, tariffs have supported domestic API production, localized component sourcing, and strengthened regional supply chains over the long term.

The short-acting b2 agonists market research report is one of a series of new reports that provides short-acting b2 agonists market statistics, including short-acting b2 agonists industry global market size, regional shares, competitors with a short-acting b2 agonists market share, detailed short-acting b2 agonists market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting b2 agonists industry. This short-acting b2 agonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Short-acting beta-2 agonists are medications commonly used to provide fast relief from asthma and other respiratory condition symptoms. They act by stimulating beta-2 adrenergic receptors in the smooth muscles of the airways, causing rapid bronchodilation or relaxation of the airway muscles.

The main types of short-acting beta-2 agonists include albuterol, levalbuterol, metaproterenol, and others. Albuterol is a widely used short-acting beta-2 agonist that quickly relieves bronchospasm by relaxing airway muscles. It is prescribed for asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchospasm and can be administered via inhalation, orally, or by injection. The end users include hospitals, clinics, and home healthcare settings.

The short-acting beta-2 agonists market consists of sales of nebulizer solutions, combination inhalers, respiratory monitoring devices, spacers and holding chambers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.